We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

86 hedge funds and large institutions have $121M invested in Invesco Biotechnology & Genome ETF in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 35 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

5% more funds holding

Funds holding: 82 → 86 (+4)

1.44% less ownership

Funds ownership: 30.87% → 29.43% (-1.4%)

9% less capital invested

Capital invested by funds: $133M → $121M (-$12M)

46% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 35

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $15K

Holders
86
Holders Change
+4
Holders Change %
+4.88%
% of All Funds
2.26%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
14
Increased
19
Reduced
35
Closed
10
Calls
–
Puts
$15K
Net Calls
-$15K
Net Calls Change
-$15K

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$4.38M
2
CFS
Commonwealth Financial Services
West Virginia
+$593K
3
Citadel Advisors
Citadel Advisors
Florida
+$451K
4
VF
Virtu Financial
New York
+$292K
5
TCM
Traynor Capital Management
Pennsylvania
+$228K

Top Sellers

Rank Fund Capital Flow
1
FIM
Freedom Investment Management
Connecticut
-$4.95M
2
Bank of America
Bank of America
North Carolina
-$4.77M
3
Morgan Stanley
Morgan Stanley
New York
-$4.33M
4
HighTower Advisors
HighTower Advisors
Illinois
-$3.9M
5
UBS Group
UBS Group
Switzerland
-$3.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
DWM
51
Dorchester Wealth Management
Quebec, Canada
$207K +$24.7K +500 +14%
Millennium Management
52
Millennium Management
New York
$205K +$200K +4,050 New
SFM
53
Signet Financial Management
New Jersey
$201K -$91.4K -1,850 -32%
WEC
54
Winslow Evans & Crocker
Massachusetts
$171K -$4.64K -94 -3%
JWM
55
Jacobus Wealth Management
Wisconsin
$160K – – –
CPIG
56
Chicago Partners Investment Group
Illinois
$137K +$134K +2,721 New
IA
57
IFP Advisors
Florida
$130K +$127K +2,570 New
GT
58
Glenmede Trust
Pennsylvania
$79K – – –
AFP
59
Ausdal Financial Partners
Iowa
$71K +$69.9K +1,415 New
BC
60
Bartlett & Co
Ohio
$51K – – –
PNC Financial Services Group
61
PNC Financial Services Group
Pennsylvania
$48K – – –
Creative Planning
62
Creative Planning
Kansas
$45K +$34.6K +700 +350%
FCCM
63
First City Capital Management
Georgia
$31.6K – – –
CFA
64
CT Financial Advisors
Pennsylvania
$30.3K +$148 +3 +0.5%
MCM
65
Manchester Capital Management
Vermont
$28K – – –
WA
66
WFG Advisors
Texas
$27K -$9.34K -189 -26%
BCM
67
Blume Capital Management
California
$18K – – –
TFA
68
Transamerica Financial Advisors
Florida
$16K – – –
NFG
69
Next Financial Group
Texas
$15K – – –
AIP
70
Ameritas Investment Partners
Nebraska
$15K +$2.96K +60 +24%
UFA
71
US Financial Advisors
Massachusetts
$15K +$14.8K +300 New
DADC
72
D.A. Davidson & Co
Montana
$14K – – –
AIA
73
Allegis Investment Advisors
Idaho
$11K +$11K +222 New
ASN
74
Advisory Services Network
Georgia
$10K +$49 +1 +0.5%
JFGIW
75
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$10K +$544 +11 +6%
1 2
3
4

PBE Hedge Fund Activity: Q4 2015 in Review

86 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2015, worth a combined $121M — down 9% from $133M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PBE positions and 10 closed out — a net gain of 4 holders — while 19 added to existing stakes and 35 trimmed.

The largest buyer was LPL Financial, adding an estimated $4.38M. The largest seller was Freedom Investment Management, exiting entirely with an estimated $4.95M sold.

  • 86 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2015, up from 82 in Q3 2015.
  • Funds reported $121M of Invesco Biotechnology & Genome ETF stock for Q4 2015, down 9% quarter-over-quarter.
  • 14 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2015 and 10 closed out, a net change of +4 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2015 was LPL Financial, an estimated $4.38M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2015 was Freedom Investment Management, an estimated $4.95M sold.

Based on aggregated 13F filings for Q4 2015.